Heritage & History 2017-11-27T15:23:06+00:00

Heritage & History

We enhance lives by providing innovative,
safe and effective healthcare solutions

Heritage & History

We enhance lives by providing innovative,
safe and effective healthcare solutions

Heritage & History

We enhance lives by providing innovative,
safe and effective healthcare solutions

The SchillersSeptodont is a pharmaceutical and medical device company and was founded in 1932 by Annie & Nestor Schiller. When Henri Schiller took the leadership of the company, Septodont launched worldwide well established brands such as Endomethasone, Alvogyl and Detartrine. At the same time, the group also positioned itself among the frontrunners of dental anaesthetics in cartridges and leader in anesthesia. To do so, Septodont acquired in 1990 a manufacturing site in France dedicated to dental needles. Then the company introduced Septocaine® in 2000 in the United States, the very first articaine-based anesthetic. In 2000, Septodont acquired Novocol, an injectable anaesthetic facility based in Canada.

Beyond dental anesthesia, Septodont also invested in R&D towards bioactive and biocompatible therapeutic solutions, which led to the introduction of Biodentine and Bioroot RCS, two products based on the ABS Technology (Active Biosilicate Technology).

The Schillers

Septodont is a pharmaceutical and medical device company and was founded in 1932 by Annie & Nestor Schiller. When Henri Schiller took the leadership of the company, Septodont launched worldwide well established brands such as Endomethasone, Alvogyl and Detartrine. At the same time, the group also positioned itself among the frontrunners of dental anaesthetics in cartridges and leader in anesthesia. To do so, Septodont acquired in 1990 a manufacturing site in France dedicated to dental needles. Then the company introduced Septocaine® in 2000 in the United States, the very first articaine-based anesthetic. In 2000, Septodont acquired Novocol, an injectable anaesthetic facility based in Canada.

Beyond dental anesthesia, Septodont also invested in R&D towards bioactive and biocompatible therapeutic solutions, which led to the introduction of Biodentine and Bioroot RCS, two products based on the ABS Technology (Active Biosilicate Technology).

A long established presence in more than 150 countries.

Dedicated to serving the needs of dental professionals wherever they are, the company extended its global presence in the world by opening foreign subsidiaries in India (1998), China (2001), Brazil (2003) and in European countries (United Kingdom, Germany, Poland, Benelux, Italy and Spain).

Between 2014 and 2016, Septodont also acquired 2 companies in Brazil (TDV in 2014, a restorative accessory manufacturer and DLA in 2016, an injectable anesthetics facility) and one in Canada (Duoject – 2015, an engineering design firm for injection devices). In 2016 a new state-of-the-art manufacturing unit for injectable anesthetics has been opened in Saint-Maur-des-Fossés (France).

The world leader in dental pain management.

With 500 million cartridges of local anesthetic produced every year, Septodont is today world leader of dental anesthesia. The group counts 1,700 employees and remains a 100% family owned company under the leadership of its CEO, Olivier Schiller.

Change Language
Local Websites
You are on the Septodont Corporate website. Choose your location to access your dedicated local website.